Jiangsu Yahong Meditech (688176) Fundamentals 2026 — Revenue Analysis | SniperIQ
Jiangsu Yahong Meditech (688176) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.5B, trading at ¥13.10 on the SHH. This SniperIQ fundamentals page covers Jiangsu Yahong Meditech's valuation, profitability (net margin -156.1%), revenue (¥277M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Yahong Meditech's market cap?
Jiangsu Yahong Meditech (688176) has a market capitalization of approximately ¥7.5B, trading at ¥13.10 on the SHH. Market cap moves with the live share price.
What is Jiangsu Yahong Meditech's P/E ratio?
Jiangsu Yahong Meditech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Yahong Meditech?
Jiangsu Yahong Meditech runs a net profit margin of -156.1%, a gross margin of 97.7%, and an operating margin of -159.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Yahong Meditech generate?
Jiangsu Yahong Meditech reported revenue of ¥277M for fiscal year 2025, with net income of -¥419M and earnings per share (EPS) of -0.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Yahong Meditech pay a dividend?
Jiangsu Yahong Meditech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Jiangsu Yahong Meditech financially healthy?
Jiangsu Yahong Meditech carries a debt-to-equity ratio of 0.23x and a current ratio of 4.07x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Yahong Meditech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Yahong Meditech (688176) the key facts are: market cap ¥7.5B, revenue ¥277M, 52-week range 8.93-18.11. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Yahong Meditech's full fundamentals live
Get Jiangsu Yahong Meditech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.